Brief Report: Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results From the SINGLE Randomized Clinical Trial

The SINGLE study was a randomized, double-blind, noninferiority study that evaluated the safety and efficacy of 50 mg dolutegravir + abacavir/lamivudine versus efavirenz/tenofovir/emtricitabine in 833 ART-naive HIV-1 + participants. Of 833 randomized participants, 71% in the dolutegravir + abacavir/...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :J Acquir Immune Defic Syndr
Главные авторы: Walmsley, Sharon, Baumgarten, Axel, Berenguer, Juan, Felizarta, Franco, Florence, Eric, Khuong-Josses, Marie-Aude, Kilby, J. Michael, Lutz, Thomas, Podzamczer, Daniel, Portilla, Joaquin, Roth, Norman, Wong, Deborah, Granier, Catherine, Wynne, Brian, Pappa, Keith
Формат: Artigo
Язык:Inglês
Опубликовано: JAIDS Journal of Acquired Immune Deficiency Syndromes 2015
Предметы:
Clinical Science
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4645960/
https://ncbi.nlm.nih.gov/pubmed/26262777
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/QAI.0000000000000790
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы